In addition, we treated ACC cell lines with 5μM Gleevec (Imatinib mesylate), the inhibitor of c-kit [23].The result showed that Gleevec had reversal of the enhanced migration and invasion ability of ACC-M (Figure S4) and ACC-2 cells with c-kit overexpression, suggesting that c-kit is required for the EMT and the migration and invasion of ACC cell lines, and targeting c-kit could be a promising therapeutic strategy for ACC metastasis. Here, KIT is linked to adrenal cortex carcinoma.